REGN vs ULS · P/E 14, rev $14.34B vs P/E 55, rev $2.87B
Regeneron Pharmaceuticals Inc (REGN) versus UL Solutions Inc. (ULS) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
UL Solutions Inc. (ULS) is a specialty business services company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported ULS revenue for 2024-12-31 was $2.87B. Net income was $345.0M. Revenue was up 7.2% from 2023-12-31 to 2024-12-31. ULS currently screens at market cap $18.97B and trailing P/E 54.7.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. ULS currently screens at market cap $18.97B and trailing P/E 54.7.
Not investment advice. Open the REGN and ULS stock pages for the full models.
Not investment advice.